Xia-qiu Zhou

833 total citations
29 papers, 553 citations indexed

About

Xia-qiu Zhou is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Xia-qiu Zhou has authored 29 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 20 papers in Hepatology and 7 papers in Molecular Biology. Recurrent topics in Xia-qiu Zhou's work include Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (17 papers) and Liver Disease Diagnosis and Treatment (11 papers). Xia-qiu Zhou is often cited by papers focused on Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (17 papers) and Liver Disease Diagnosis and Treatment (11 papers). Xia-qiu Zhou collaborates with scholars based in China, Australia and United States. Xia-qiu Zhou's co-authors include Lungen Lu, Jiyao Wang, Jiqiang Li, Minde Zeng, Cheng‐Wei Chen, Xiong Cai, Yimin Mao, Qing Xie, Shisan Bao and Qing Guo and has published in prestigious journals such as Hepatology, Brain Research and Journal of Hepatology.

In The Last Decade

Xia-qiu Zhou

28 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xia-qiu Zhou China 11 445 414 65 27 25 29 553
Marta Flisiak‐Jackiewicz Poland 10 262 0.6× 99 0.2× 76 1.2× 15 0.6× 13 0.5× 22 347
Theresa Maria Holtmann Germany 5 177 0.4× 122 0.3× 130 2.0× 10 0.4× 43 1.7× 10 321
A Tandon India 8 216 0.5× 269 0.6× 80 1.2× 27 1.0× 11 0.4× 12 462
Nadège Barri‐Ova France 7 356 0.8× 204 0.5× 63 1.0× 11 0.4× 6 0.2× 8 445
Giulio De Stefano Italy 4 175 0.4× 127 0.3× 65 1.0× 30 1.1× 24 1.0× 6 261
Natsuko Hada Japan 5 301 0.7× 128 0.3× 125 1.9× 6 0.2× 41 1.6× 6 419
Julien Chaigneau France 9 199 0.4× 153 0.4× 37 0.6× 8 0.3× 10 0.4× 19 281
Lungen Lu China 11 138 0.3× 126 0.3× 92 1.4× 8 0.3× 36 1.4× 27 315
Juan del Olmo Spain 9 177 0.4× 151 0.4× 100 1.5× 10 0.4× 8 0.3× 11 332
Monica McCarthy United States 3 317 0.7× 303 0.7× 20 0.3× 14 0.5× 18 0.7× 6 384

Countries citing papers authored by Xia-qiu Zhou

Since Specialization
Citations

This map shows the geographic impact of Xia-qiu Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xia-qiu Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xia-qiu Zhou more than expected).

Fields of papers citing papers by Xia-qiu Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xia-qiu Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xia-qiu Zhou. The network helps show where Xia-qiu Zhou may publish in the future.

Co-authorship network of co-authors of Xia-qiu Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xia-qiu Zhou. A scholar is included among the top collaborators of Xia-qiu Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xia-qiu Zhou. Xia-qiu Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jia, Jidong, Jinlin Hou, Deming Tan, et al.. (2013). Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatology International. 8(1). 72–82. 13 indexed citations
2.
Wu, Shanming, Xia-qiu Zhou, Qingbo Zhang, et al.. (2011). [Clinical characteristics of 638 patients infected with hepatitis C virus by post blood transfusion, in Shanghai].. PubMed. 32(4). 388–91. 3 indexed citations
3.
Cai, Wei, Qing Xie, Baoyan An, et al.. (2010). On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. Journal of Clinical Virology. 48(1). 22–26. 69 indexed citations
4.
Gui, Honglian, Haowei Wang, Yun Wu, et al.. (2010). Significant histopathology in Chinese chronic hepatitis B patients with persistently high–normal alanine aminotransferase. Journal of Viral Hepatitis. 17(s1). 44–50. 48 indexed citations
5.
Xiang, Xiaogang, Jie Lu, Zhixia Dong, et al.. (2010). Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. Infection Genetics and Evolution. 11(2). 382–390. 7 indexed citations
6.
7.
Hsu, Chao‐Wei, Yun‐Fan Liaw, Lai Wei, et al.. (2009). 906 EFFICACY OF 3 YEARS OF TELBIVUDINE TREATMENT FOR PATIENTS WITH GENOTYPE B/C CHRONIC HEPATITIS B (CHB). Journal of Hepatology. 50. S329–S329.
8.
Ren, Hong, et al.. (2009). [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].. PubMed. 17(12). 881–6. 10 indexed citations
9.
Yao, Guangbi, Xia-qiu Zhou, Bao-en Wang, et al.. (2007). Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatology International. 1(3). 373–381. 9 indexed citations
10.
Yu, Yanyan, et al.. (2006). [Foscarnet sodium for treatment in patients with severe chronic hepatitis B].. PubMed. 14(11). 814–6. 2 indexed citations
11.
Zeng, Minde, Lungen Lu, Yimin Mao, et al.. (2005). Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model†. Hepatology. 42(6). 1437–1445. 139 indexed citations
12.
Liu, Haifang, Qing Xie, Shan Jiang, et al.. (2005). [Inhibition of mouse hepatocyte apoptosis by anti-caspase-12 small interfering RNA].. PubMed. 13(12). 923–6. 1 indexed citations
13.
Lu, Lungen, Minde Zeng, Yimin Mao, et al.. (2003). Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial. World Journal of Gastroenterology. 9(11). 2480–2480. 69 indexed citations
14.
Lu, Lungen, Minde Zeng, Mobin Wan, et al.. (2003). Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World Journal of Gastroenterology. 9(11). 2574–2574. 66 indexed citations
15.
Li, Guangming, Qing Xie, Xia-qiu Zhou, et al.. (2003). Taurodeoxycholic acid induced apoptosis via mitochondrial injury in HepG2 cells. World Chinese Journal of Digestology. 11(8). 1148–1151. 1 indexed citations
16.
Xie, Qing, Guangming Li, Xia-qiu Zhou, et al.. (2003). [Effect of Tauroursodeoxycholic acid on cytochrome C-mediated apoptosis in HepG2 cells].. PubMed. 11(5). 298–301. 2 indexed citations
17.
Weng, Honglei, Weimin Cai, Bao-en Wang, et al.. (2003). [Clinical study of anti-hepatic fibrosis effect of IFN-gamma in patients with chronic hepatitis B].. PubMed. 83(11). 943–7. 4 indexed citations
18.
Liu, Jing, Feng Xu, Qing Xie, et al.. (2001). Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozymein vitro andin vivo. Science in China Series C Life Sciences. 44(6). 618–627. 3 indexed citations
19.
Liu, Jing, Xianwen Chen, Feng Xu, et al.. (2001). Ribozyme-mediated inhibition of caspase-3 activity reduces apoptosis induced by 6-hydroxydopamine in PC12 cells. Brain Research. 899(1-2). 10–19. 30 indexed citations
20.
Jiang, Shan, et al.. (2000). [Preparation and identification of hammerhead ribozyme in vitro against caspase-12 mRNA fragments].. PubMed. 13(2). 121–3. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Flisiak‐Jackiewicz Breakdown of academic impact, for papers by Theresa Maria Holtmann Breakdown of academic impact, for papers by A Tandon Breakdown of academic impact, for papers by Nadège Barri‐Ova Breakdown of academic impact, for papers by Giulio De Stefano Breakdown of academic impact, for papers by Natsuko Hada Breakdown of academic impact, for papers by Julien Chaigneau Breakdown of academic impact, for papers by Lungen Lu Breakdown of academic impact, for papers by Juan del Olmo Breakdown of academic impact, for papers by Monica McCarthy
Rankless by CCL
2026